Grace Therapeutics, Inc. (GRCE)

Several key events have impacted Grace Therapeutics, Inc.'s stock price in the past six months. The FDA established April 23, 2026, as the PDUFA target date for GTx-104, boosting investor confidence. Positive Phase 3 clinical trial data for GTx-104 demonstrated a 19% reduction in clinically significant hypotension and improved functional outcomes. The company reported a significant reduction in net loss for Q3 fiscal 2026. Grace Therapeutics secured approximately $4.0 million through warrant exercises and obtained a new U.S. patent for GTx-104, extending intellectual property protection to 2043. Favorable trends in the broader biotech market have also contributed to investor sentiment. As of April 10, 2026, the stock has shown a 79.50% increase over the last year, but experienced a -25.52% fall compared to the previous week and a -9.11% fall over the last month, with a 52-week range between $1.88 and $5.18.

Information regarding the demand seasonality for Grace Therapeutics, Inc.'s products and services is not available. Demand is typically driven by disease incidence and diagnosis rather than seasonal factors.

Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing pharmaceutical products for rare and orphan diseases, operating within the Healthcare sector and the Biotechnology/Pharmaceuticals industry. The company specializes in addressing unmet medical needs through drug candidates such as GTx-104, an intravenous infusion for aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, an oral mucosal spray of betamethasone for Ataxia-Telangiectasia (A-T); GTx-101, a topical bioadhesive film for postherpetic neuralgia (PHN); and GTx-201. Formerly known as Acasti Pharma Inc., the company changed its name to Grace Therapeutics, Inc. in October 2024.

Grace Therapeutics, Inc. is headquartered in Princeton, New Jersey, United States, and engages in the development and commercialization of pharmaceutical products in Canada. While the company aims to reach a global patient base and holds a strong multi-layered intellectual property portfolio spanning the world, specific operational locations or major market countries beyond Canada are not explicitly detailed.

Grace Therapeutics, Inc. has actively engaged in activities that contribute positively to its brand reputation. The company has presented data on GTx-104 at medical conferences and participated in healthcare investor conferences. The company's return to its original name, Grace Therapeutics, in October 2024, was intended to reflect its extensive scientific accomplishments. No specific events negatively affecting its reputation in the past year were found.

Grace Therapeutics, Inc. has a diverse ownership structure, including institutional, individual, and retail investors. As of April 8, 2026, 23 institutional owners hold a total of 4,327,617 shares, with key shareholders including Nantahala Capital Management, LLC, and Vanguard Group Inc. The largest individual shareholder is Grace 2018 Irrevocable Trust Rajitha, owning 30.31% of the company's shares.